)
)
)
Model Medicines is an AI-native biotechnology company developing first-in-class small-molecule therapeutics by targeting conserved biological choke points that drive disease across multiple indications. Its proprietary discovery platform integrates multimodal AI, generative chemistry, and predictive safety modeling to enable end-to-end drug discovery, from novel target identification through preclinical proof-of-concept. The lead program, MDL-001, is the first oral, direct-acting, non-nucleoside antiviral targeting a previously undiscovered allosteric site in viral RNA-dependent RNA polymerase (RdRp Thumb-1). MDL-001 has demonstrated broad-spectrum preclinical efficacy across respiratory and liver viruses, including SARS-CoV-2, influenza, RSV, HCV, HBV, and HDV, and is advancing toward IND submission in late 2026. MDL-001 was presented at IDWeek, The Liver Meeting® (AASLD), and HepDART. Model Medicines was recently named a Fierce 15 company and selected for BARDA’s VANGUARD program.
Year Founded
2019
Next catalyst (value inflection) update
The next major value inflection for Model Medicines will be the completion of IND-enabling studies and regulatory submission for MDL-001, our first-in-class, oral, broad-spectrum antiviral, targeted for late 2026, enabling clinical trial initiation. This milestone is supported by continued data readouts from in vivo efficacy, safety, and CMC scale-up. Additional catalysts include advancement of MDL-4102 through preclinical optimization toward IND submission in early 2027, as well as new partnership announcements stemming from our drug discovery under mandate programs and platform collaborations. Together, these milestones further validate the translational readiness and repeatability of our AI-driven discovery platform.
Expected time of next catalyst update
Jul-26
City
San Diego
Country
United States
Company CEO or top company official
Daniel Haders PhD
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
MDL-001 – A first-in-class, oral, direct-acting, broad-spectrum antiviral targeting the conserved RdRp Thumb-1 allosteric site. MDL-001 has demonstrated preclinical efficacy across respiratory and liver viruses, including SARS-CoV-2, influenza, RSV, HCV, HBV, and HDV, and is advancing toward IND submission in late 2026. MDL-4102 – A first-in-class, highly selective small-molecule BRD4 inhibitor designed to overcome the dose-limiting toxicities associated with prior BET inhibitors. Discovered through record-scale AI-driven virtual screening, MDL-4102 is advancing through preclinical development toward IND submission in early 2027.
Number of Unlicensed Products
This includes two lead unlicensed clinical-stage candidates (MDL-001 and MDL-4102), additional pipeline programs in virology and oncology, and drug discovery under mandate programs available for strategic partnership and co-development.
Therapeutic Area
Infectious Diseases
Website
https://modelmedicines.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
